Clinical Relevance of Advanced Glycation Endproducts for Vascular Surgery

European Journal of Vascular and Endovascular Surgery

Volumn 36, Issue 2, 2008, Pages 125-131

  Meerwaldt, R ^a   van der Vaart, M G ^b   van Dam, G M ^b   Tio, R A ^b   Hillebrands, J L ^b   Smit, A J ^b   Zeebregts, C J ^b  

^a ISALA HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Advanced glycation; Diabetic foot; Patency; Plaque vulnerability; Vascular surgery

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIDOXAMINE;

AORTA OCCLUSION; ARTERY OCCLUSION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CALCIUM ANTAGONISM; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CLINICAL ASSESSMENT; DIABETIC FOOT; DISEASE ASSOCIATION; DISEASE COURSE; GRAFT PATENCY; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TISSUE INJURY; VASCULAR PATENCY; VASCULAR SURGERY;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CARDIOVASCULAR DISEASES; DIABETIC FOOT; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; GRAFT OCCLUSION, VASCULAR; HUMANS; STENTS; TREATMENT OUTCOME; VASCULAR PATENCY; VASCULAR SURGICAL PROCEDURES;

EID: 46749149242     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2008.01.030     Document Type: Review

References (64)

1. Monnier V.M., Mustata G.T., Biemel K.L., Reihl O., Lederer M.O., Zhenyu D., et al. Cross-linking of the extracellular matrix by the Maillard reaction in aging and diabetes: an update on "a Puzzle Nearing Resolution". Ann N Y Acad Sci 1043 (2005) 533-544
2. Baynes J.W. From life to death - the struggle between chemistry and biology during aging: the Maillard reaction as an amplifier of genomic damage. Biogerontology 1 3 (2000) 235-246
3. Miyata T., Wada Y., Cai Z., Iida Y., Horie K., Yasuda Y., et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51 4 (1997) 1170-1181
4. Baynes J.W., and Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48 1 (1999) 1-9
5. Monnier V.M. Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol 45 4 (1990) B105-B111
6. Baynes J.W., and Thorpe S.R. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28 12 (2000) 1708-1716
7. Thorpe S.R., and Baynes J.W. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25 3-4 (2003) 275-281
8. Miyata T., Ueda Y., Yoshida A., Sugiyama S., Iida Y., Jadoul M., et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 51 3 (1997) 880-887
9. Koschinsky T., He C.J., Mitsuhashi T., Bucala R., Liu C., Buenting C., et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94 12 (1997) 6474-6479
10. Cerami C., Founds H., Nicholl I., Mitsuhashi T., Giordano D., Vanpatten S., et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 94 25 (1997) 13915-13920
11. He C., Sabol J., Mitsuhashi T., and Vlassara H. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48 6 (1999) 1308-1315
12. Klein D.J., Oegema Jr. T.R., and Brown D.M. Release of glomerular heparan-35so4 proteoglycan by heparin from glomeruli of streptozocin-induced diabetic rats. Diabetes 38 1 (1989) 130-139
13. Drueke T.B., Khoa T.N., Massy Z.A., Witko-Sarsat V., Lacour B., and Descamps-Latscha B. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int Suppl 78 (2001) S114-S119
14. Thornalley P.J. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy -le-grand) 44 7 (1998) 1013-1023
15. Wautier J.L., and Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95 3 (2004) 233-238
16. Monnier V.M., Vishwanath V., Frank K.E., Elmets C.A., Dauchot P., and Kohn R.R. Relation between complications of type i diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314 7 (1986) 403-408
17. Onorato J.M., Thorpe S.R., and Baynes J.W. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann N Y Acad Sci 854 (1998) 277-290
18. Hricik D.E., Wu Y.C., Schulak A., and Friedlander M.A. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Clin Transplant 10 6 Pt 1 (1996) 568-573
19. Meerwaldt R., Hartog J.W., Graaff R., Huisman R.J., Links T.P., den Hollander N.C., et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16 12 (2005) 3687-3693
20. Meerwaldt R., Graaff R., Oomen P.H., Links T.P., Jager J.J., Alderson N.L., et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47 7 (2004) 1324-1330
21. Yoshida N., Okumura K., and Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 54 3 (2005) 345-350
22. Suliman M.E., Stenvinkel P., Jogestrand T., Maruyama Y., Qureshi A.R., Barany P., et al. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 66 6 (2006) 418-425
23. Crauwels H.M., Herman A.G., and Bult H. Local application of advanced glycation end products and intimal hyperplasia in the rabbit collared carotid artery. Cardiovasc Res 47 1 (2000) 173-182
24. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Cuccurullo C., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108 9 (2003) 1070-1077
25. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T.A., Sakamoto K., Nakatani Y., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28 11 (2005) 2716-2721
26. Koyama H., Shoji T., Yokoyama H., Motoyama K., Mori K., Fukumoto S., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25 12 (2005) 2587-2593
27. Wang K., Zhou Z., Zhang M., Fan L., Forudi F., Zhou X., et al. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 317 1 (2006) 37-43
28. Yoshida S., Yamada K., Hamaguchi K., Nishimura M., Hatakeyama E., Tsuchida H., et al. Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation. Clin Nephrol 49 5 (1998) 273-280
29. McNulty M., Mahmud A., and Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens 20 3 (2007) 242-247
30. Akira K., Amano M., Okajima F., Hashimoto T., and Oikawa S. Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits. Biol Pharm Bull 29 1 (2006) 75-81
31. Lapolla A., Piarulli F., Sartore G., Ceriello A., Ragazzi E., Reitano R., et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 30 3 (2007) 670-676
32. Blaauw J., Smit A.J., van Pampus M.G., van Doormaal J.J., Aarnoudse J.G., Rakhorst G., et al. Skin autofluorescence, a marker of advanced glycation end products and oxidative stress, is increased in recently preeclamptic women. Am J Obstet Gynecol 195 3 (2006) 717-722
33. Kiuchi K., Nejima J., Takano T., Ohta M., and Hashimoto H. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85 1 (2001) 87-91
34. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25 5 (2005) 1032-1037
35. Fuellen G., Foell D., Nacken W., Sorg C., and Kerkhoff C. Absence of S100A12 in mouse: implications for RAGE-S100A12 interaction. Trends Immunol 24 12 (2003) 622-624
36. Burke A.P., Kolodgie F.D., Zieske A., Fowler D.R., Weber D.K., Varghese P.J., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 24 7 (2004) 1266-1271
37. Mulder D.J., van Haelst P.L., Gross S., de Leeuw K., Bijzet J., Graaff R., et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis (2007)
38. Berg T.J., Snorgaard O., Faber J., Torjesen P.A., Hildebrandt P., Mehlsen J., et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22 7 (1999) 1186-1190
39. Zoccali C., Mallamaci F., Asahia K., Benedetto F.A., Tripepi G., Tripepi R., et al. Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. J Nephrol 14 4 (2001) 293-298
40. Simm A., Wagner J., Gursinsky T., Nass N., Friedrich I., Schinzel R., et al. Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery?. Exp Gerontol 42 7 (2007) 668-675
41. Koyama Y., Takeishi Y., Arimoto T., Niizeki T., Shishido T., Takahashi H., et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 13 3 (2007) 199-206
42. Kilhovd B.K., Juutilainen A., Lehto S., Ronnemaa T., Torjesen P.A., Hanssen K.F., et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 50 7 (2007) 1409-1417
43. Meerwaldt R., Lutgers H.L., Links T.P., Graaff R., Baynes J.W., Gans R.O., et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30 1 (2007) 107-112
44. Goldberg T., Cai W., Peppa M., Dardaine V., Baliga B.S., Uribarri J., et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104 8 (2004) 1287-1291
45. Fung F., Sherrard D.J., Gillen D.L., Wong C., Kestenbaum B., Seliger S., et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 40 2 (2002) 307-314
46. Wu T., Rifai N., Willett W.C., and Rimm E.B. Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men. Am J Epidemiol 166 5 (2007) 544-551
47. Cuccurullo C., Iezzi A., Fazia M.L., De Cesare D., Di Francesco A., Muraro R., et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 26 12 (2006) 2716-2723
48. Kolodgie F.D., Narula J., Haider N., and Virmani R. Apoptosis in atherosclerosis. Does it contribute to plaque instability?. Cardiol Clin 19 1 (2001) 127-139 ix
49. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 22 (2002) 2827-2835
50. Sugimoto K., Nishizawa Y., Horiuchi S., and Yagihashi S. Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 40 12 (1997) 1380-1387
51. Cellek S., Qu W., Schmidt A.M., and Moncada S. Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia 47 2 (2004) 331-339
52. Meerwaldt R., Links T.P., Graaff R., Hoogenberg K., Lefrandt J.D., Baynes J.W., et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 48 8 (2005) 1637-1644
53. Veves A., Akbari C.M., Primavera J., Donaghue V.M., Zacharoulis D., Chrzan J.S., et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 47 3 (1998) 457-463
54. Goova M.T., Li J., Kislinger T., Qu W., Lu Y., Bucciarelli L.G., et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 159 2 (2001) 513-525
55. Zhou Z., Wang K., Penn M.S., Marso S.P., Lauer M.A., Forudi F., et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107 17 (2003) 2238-2243
56. Takeda R., Suzuki E., Satonaka H., Oba S., Nishimatsu H., Omata M., et al. Blockade of endogenous cytokines mitigates neointimal formation in obese zucker rats. Circulation 111 11 (2005) 1398-1406
57. Choi E.Y., Kwon H.M., Ahn C.W., Lee G.T., Joung B., Hong B.K., et al. Serum levels of advanced glycation end products are associated with in-stent restenosis in diabetic patients. Yonsei Med J 46 1 (2005) 78-85
58. Cai W., Zhu L., Chen X., Uribarri J., and Peppa M. Association of advanced glycoxidation end products and inflammation markers with thrombosis of arteriovenous grafts in hemodialysis patients. Am J Nephrol 26 2 (2006) 181-185
59. Weiss M.F., Scivittaro V., and Anderson J.M. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis 37 5 (2001) 970-980
60. Monnier V.M., Bautista O., Kenny D., Sell D.R., Fogarty J., Dahms W., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 48 4 (1999) 870-880
61. Metz T.O., Alderson N.L., Thorpe S.R., and Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 419 1 (2003) 41-49
62. Alderson N.L., Chachich M.E., Youssef N.N., Beattie R.J., Nachtigal M., Thorpe S.R., et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63 6 (2003) 2123-2133
63. Sebekova K., Gazdikova K., Syrova D., Blazicek P., Schinzel R., Heidland A., et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 17 4 (2003) 265-270
64. Wolffenbuttel B.H., Boulanger C.M., Crijns F.R., Huijberts M.S., Poitevin P., Swennen G.N., et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 95 8 (1998) 4630-4634